| Year |
Citation |
Score |
| 2023 |
Esfahanian N, Chan SWS, Zhan LJ, Brown MC, Khan K, Lee J, Balaratnam K, Yan E, Parker J, Garcia-Pardo M, Barghout SH, Eng L, Bradbury PA, Shepherd FA, Leighl NB, ... ... Juergens R, et al. Presentation and outcomes of KRAS mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence. Cancer Treatment and Research Communications. 37: 100774. PMID 37979334 DOI: 10.1016/j.ctarc.2023.100774 |
0.351 |
|
| 2023 |
Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nature Medicine. 29: 2559-2569. PMID 37814061 DOI: 10.1038/s41591-023-02598-9 |
0.359 |
|
| 2023 |
Li Y, Juergens RA, Finley C, Swaminath A. Moving Through Inertia - The Promise of Current and Future Treatment Options in the Management of Stage III Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 37574133 DOI: 10.1016/j.jtho.2023.08.011 |
0.388 |
|
| 2023 |
Rupp M, Fanton-Aita F, Snow S, Wheatley-Price P, Melosky B, Juergens RA, Chu Q, Blais N, Banerji S, Ng R, Khoudigian S, Sharma A, On PV, Liu G. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology (Toronto, Ont.). 30: 6559-6574. PMID 37504341 DOI: 10.3390/curroncol30070481 |
0.325 |
|
| 2023 |
Cheema PK, Banerji SO, Blais N, Chu QS, Juergens RA, Leighl NB, Sacher A, Sheffield BS, Snow S, Vincent M, Wheatley-Price PF, Yip S, Melosky BL. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. Current Oncology (Toronto, Ont.). 30: 6473-6496. PMID 37504336 DOI: 10.3390/curroncol30070476 |
0.353 |
|
| 2023 |
Melosky BL, Leighl NB, Dawe D, Blais N, Wheatley-Price PF, Chu QS, Juergens RA, Ellis PM, Sun A, Schellenberg D, Ionescu DN, Cheema PK. Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer. Current Oncology (Toronto, Ont.). 30: 6289-6315. PMID 37504325 DOI: 10.3390/curroncol30070465 |
0.35 |
|
| 2022 |
Ezeife DA, Spackman E, Juergens RA, Laskin JJ, Agulnik JS, Hao D, Laurie SA, Law JH, Le LW, Kiedrowski LA, Melosky B, Shepherd FA, Cohen V, Wheatley-Price P, Vandermeer R, et al. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 14: 17588359221112696. PMID 35923926 DOI: 10.1177/17588359221112696 |
0.342 |
|
| 2022 |
Febbraro M, Gheware A, Kennedy T, Jain D, de Moraes FY, Juergens R. Barriers to Access: Global Variability in Implementing Treatment Advances in Lung Cancer. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 42: 1-7. PMID 35427189 DOI: 10.1200/EDBK_351021 |
0.338 |
|
| 2021 |
Cheema PK, Banerji SO, Blais N, Chu QS, Desmeules P, Juergens RA, Leighl NB, Sheffield BS, Wheatley-Price PF, Melosky BL. Canadian Consensus Recommendations on the Management of -Altered NSCLC. Current Oncology (Toronto, Ont.). 28: 4552-4576. PMID 34898564 DOI: 10.3390/curroncol28060386 |
0.383 |
|
| 2021 |
Melosky B, Cheema P, Juergens RA, Leighl NB, Liu G, Wheatley-Price P, Sacher A, Snow S, Tsao MS, McLeod D, Chu Q. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 13: 17588359211056306. PMID 34804219 DOI: 10.1177/17588359211056306 |
0.415 |
|
| 2021 |
Melosky B, Wheatley-Price P, Juergens RA, Sacher A, Leighl NB, Tsao MS, Cheema P, Snow S, Liu G, Card PB, Chu Q. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). PMID 34353680 DOI: 10.1016/j.lungcan.2021.06.002 |
0.388 |
|
| 2021 |
Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, et al. Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada. Lung Cancer (Amsterdam, Netherlands). PMID 33980420 DOI: 10.1016/j.lungcan.2021.04.022 |
0.462 |
|
| 2020 |
Melosky B, Cheema PK, Brade A, McLeod D, Liu G, Wheatley Price P, Jao K, Schellenberg DD, Juergens R, Leighl N, Chu Q. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer. The Oncologist. PMID 32860288 DOI: 10.1634/Theoncologist.2020-0193 |
0.543 |
|
| 2020 |
Colomer-Lahiguera S, Bryant-Lukosius D, Rietkoetter S, Martelli L, Ribi K, Fitzpatrick-Lewis D, Sherifali D, Orcurto A, Juergens R, Eicher M. Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review. Journal of Patient-Reported Outcomes. 4: 1-9. PMID 32676785 DOI: 10.1186/S41687-020-00210-Z |
0.343 |
|
| 2020 |
Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, ... Juergens RA, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. The Lancet. Oncology. PMID 32653053 DOI: 10.1016/S1470-2045(20)30326-0 |
0.345 |
|
| 2020 |
Melosky B, Banerji S, Blais N, Chu Q, Juergens R, Leighl NB, Liu G, Cheema P. Canadian consensus: a new systemic treatment algorithm for advanced mutated non-small-cell lung cancer. Current Oncology (Toronto, Ont.). 27: e146-e155. PMID 32489263 DOI: 10.3747/Co.27.6007 |
0.457 |
|
| 2020 |
Juergens RA, Hao D, Ellis PM, Tu D, Mates M, Kollmannsberger C, Bradbury PA, Tehfe M, Wheatley-Price P, Robinson A, Bebb G, Laskin J, Goffin J, Hilton J, Tomiak A, et al. A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. Lung Cancer (Amsterdam, Netherlands). 143: 1-11. PMID 32169783 DOI: 10.1016/J.Lungcan.2020.02.016 |
0.478 |
|
| 2020 |
Lu Z, Zou J, Li S, Topper MJ, Tao Y, Zhang H, Jiao X, Xie W, Kong X, Vaz M, Li H, Cai Y, Xia L, Huang P, Rodgers K, ... ... Juergens RA, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. PMID 32103175 DOI: 10.1038/S41586-020-2054-X |
0.432 |
|
| 2020 |
Nehra J, Bradbury PA, Ellis PM, Laskin J, Kollmannsberger C, Hao D, Juergens RA, Goss G, Wheatley-Price P, Hotte SJ, Gelmon K, Tinker AV, Brown-Walker P, Gauthier I, Tu D, et al. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. Investigational New Drugs. PMID 32020438 DOI: 10.1007/S10637-020-00904-7 |
0.421 |
|
| 2020 |
Yusuf D, Ko JJ, Cho H, Sheremeto C, Wang Y, Juergens RA, Ellis PM, Billawala A, Kay A, Kulkarni S, Elfiki TA, Gupta R, Naccarato K, Pennetti A, Patel D, et al. Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada. Journal of Clinical Oncology. 38: 54-54. DOI: 10.1200/Jco.2020.38.5_Suppl.54 |
0.544 |
|
| 2020 |
Sebastian M, Audigier-Valette C, Butts CA, Debieuvre D, Dixmier A, Gröschel A, Gutz S, Juergens RA, Labbe C, Moro-Sibilot D, Perol M, Schumann C, Juarez-Garcia A, Lakhdari K, Penrod JR, et al. Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E21714 |
0.525 |
|
| 2020 |
Juergens RA, Ezeife DA, Laskin JJ, Agulnik JS, Hao D, Laurie SA, Law JH, Le LW, Kiedrowski LA, Shepherd FA, Cohen V, Shokoohi A, Vandermeer R, Li JJ, Hanson I, et al. Demonstrating the value of liquid biopsy for lung cancer in a public health care system. Journal of Clinical Oncology. 38: 3546-3546. DOI: 10.1200/Jco.2020.38.15_Suppl.3546 |
0.482 |
|
| 2020 |
Seow H, Tanuseputro P, Barbera LC, Earle C, Guthrie D, Isenberg S, Juergens RA, Brouwers MC, Myers J, Sutradhar R. Development and validation of a risk prediction model for poor performance status and severe symptoms among cancer patients. Journal of Clinical Oncology. 38: 12097-12097. DOI: 10.1200/Jco.2020.38.15_Suppl.12097 |
0.321 |
|
| 2019 |
Dawe DE, Harlos CH, Juergens RA. Immuno-oncology-the new paradigm of lung cancer treatment. Current Oncology. 27. PMID 32368177 DOI: 10.3747/Co.27.5183 |
0.542 |
|
| 2019 |
Frueh M, Rahma OE, Pachynski RK, Mazieres J, Goldschmidt J, Ton TGN, Mhatre SK, Chuo CY, Martinalbo J, Davies J, Juergens R. Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: ii65. PMID 32131319 DOI: 10.1093/Annonc/Mdz063.077 |
0.526 |
|
| 2019 |
Wang Y, Van Dam A, Slaven M, Ellis KJ, Goffin JR, Juergens RA, Ellis PM. Resource use in the last three months of life by lung cancer patients in southern Ontario. Current Oncology (Toronto, Ont.). 26: 247-252. PMID 31548804 DOI: 10.3747/Co.26.4967 |
0.342 |
|
| 2019 |
Melosky B, Juergens R, McLeod D, Leighl N, Brade A, Card PB, Chu Q. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 134: 259-267. PMID 31319991 DOI: 10.1016/J.Lungcan.2019.05.027 |
0.53 |
|
| 2019 |
Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, Tsao MS, Card PB, Chu Q. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. The Oncologist. PMID 31138727 DOI: 10.1634/Theoncologist.2019-0027 |
0.554 |
|
| 2019 |
Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, Laskin J, Leighl N, MacRae R, Nicholas G, Roberge D, et al. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. Current Oncology (Toronto, Ont.). 26: e81-e93. PMID 30853813 DOI: 10.3747/Co.26.4116 |
0.532 |
|
| 2019 |
Juergens RA, Zukotynski KA, Juneau D, Krnezich L, Simms R, Forbes J, Burak ES, Valliant J, Stafford L, Armor T, Molnar I, Saad F. A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors. Journal of Clinical Oncology. 37: TPS3152-TPS3152. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps3152 |
0.36 |
|
| 2019 |
Juergens RA, Chu QS, Renouf DJ, Laurie SA, Purcea D, McWhirter E, Arndt D, Gelmon KA, Hilton J, Gavillet B, Ellis PM, Sawyer MB, Kollmannsberger CK, Andrews Wright N, Rouits E, et al. A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies. Journal of Clinical Oncology. 37: 2599-2599. DOI: 10.1200/Jco.2019.37.15_Suppl.2599 |
0.389 |
|
| 2019 |
Juergens R, Ellis P, Tu D, Hao D, Laurie S, Mates M, Goss G, Goffin J, Bradbury P, Tehfe M, Kollmansberger C, Brown-Walker P, Smoragiewicz M, Tsao M, Seymour L. MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226 Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.586 |
0.437 |
|
| 2018 |
Juergens RA, Mariano C, Jolivet J, Finn N, Rothenstein J, Reaume MN, Faghih A, Labbé C, Owen S, Shepherd FA, Villeneuve J, Romeyer F, Pettersson F, Butts C. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. Current Oncology (Toronto, Ont.). 25: 384-392. PMID 30607113 DOI: 10.3747/Co.25.4287 |
0.515 |
|
| 2018 |
Melosky B, Cheema P, Agulnik J, Albadine R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, Hirsh V, Ionescu DN, Juergens R, Morzycki W, Poonja Z, et al. Canadian perspectives: update on inhibition of -positive tumours in advanced non-small-cell lung cancer. Current Oncology (Toronto, Ont.). 25: 317-328. PMID 30464681 DOI: 10.3747/Co.25.4379 |
0.512 |
|
| 2018 |
Goffin JR, Nicholas G, Mates M, Tu D, Chen E, Laurie SA, Juergens R, Robinson A, Goss G, Reaume M, Sun S, Christink K, Maize C, MacFarlan S, Sun X, et al. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. Investigational New Drugs. PMID 30317534 DOI: 10.1007/S10637-018-0680-Z |
0.425 |
|
| 2018 |
Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N. Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29802888 DOI: 10.1016/J.Jtho.2018.05.015 |
0.536 |
|
| 2018 |
Melosky B, Chu Q, Juergens RA, Leighl N, Ionescu D, Tsao MS, McLeod D, Hirsh V. Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. Cancer Treatment Reviews. 65: 65-77. PMID 29567557 DOI: 10.1016/J.Ctrv.2018.02.005 |
0.474 |
|
| 2018 |
Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN. Standardizing biomarker testing for Canadian patients with advanced lung cancer. Current Oncology (Toronto, Ont.). 25: 73-82. PMID 29507487 DOI: 10.3747/Co.25.3867 |
0.522 |
|
| 2018 |
Colomer-Lahiguera S, Bryant-Lukosius D, Rietkoetter S, Martelli L, Ribi K, Orcurto A, Juergens R, Eicher M. The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy341.028 |
0.381 |
|
| 2018 |
Fahim C, Agzarian J, Hanna W, Juergens R, Shargall Y, Simunovic M. 200PD High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: A case series in a tertiary cancer center Journal of Thoracic Oncology. 13. DOI: 10.1016/S1556-0864(18)30473-8 |
0.346 |
|
| 2018 |
Antonia S, Gettinger S, Borghaei H, Goldman J, Brahmer J, Ready N, Gerber D, Chow L, Juergens R, Laurie S, Shepherd F, Li X, Li A, Geese W, Hellmann M. P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012 Journal of Thoracic Oncology. 13: S458. DOI: 10.1016/J.Jtho.2018.08.558 |
0.327 |
|
| 2018 |
Cheema P, Liu G, Burkes R, Owen S, Yu J, Hao D, Rothenstein J, Martel S, Iqbal M, Juergens R, Lam W, Laskin J. P2.13-13 Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.1408 |
0.475 |
|
| 2017 |
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England Journal of Medicine. 376: 2415-2426. PMID 28636851 DOI: 10.1056/Nejmoa1613493 |
0.483 |
|
| 2017 |
Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS. Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. Current Oncology (Toronto, Ont.). 24: 111-119. PMID 28490925 DOI: 10.3747/Co.24.3524 |
0.491 |
|
| 2017 |
Iafolla MAJ, Juergens RA. Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology. 7: 67. PMID 28428947 DOI: 10.3389/Fonc.2017.00067 |
0.461 |
|
| 2017 |
Nguyen NA, Isfahanian N, Pond G, Hanna W, Cutz JC, Wright J, Swaminath A, Shargall Y, Chow T, Wierzbicki M, Okawara G, Quan K, Finley C, Juergens R, Tsakiridis T. A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574). Clinical Lung Cancer. PMID 28215851 DOI: 10.1016/J.Cllc.2017.01.007 |
0.492 |
|
| 2017 |
Juergens RA, Bratman SV, Tsao MS, Laurie SA, Sara Kuruvilla M, Razak AR, Hansen AR. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. Cancer Treatment Reviews. 54: 43-57. PMID 28192747 DOI: 10.1016/J.Ctrv.2017.01.003 |
0.501 |
|
| 2017 |
Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, O JH, Gabrielson EW, Shankar LK, et al. A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC. Ejnmmi Research. 7: 8. PMID 28102506 DOI: 10.1186/S13550-017-0258-3 |
0.341 |
|
| 2017 |
Goldman JW, Antonia SJ, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Li A, Li X, Hellmann MD. Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012. Journal of Clinical Oncology. 35: 9093-9093. DOI: 10.1200/Jco.2017.35.15_Suppl.9093 |
0.395 |
|
| 2017 |
Chu QS, Herpen Cv, Leighl NB, Markman B, Clarke S, Juergens RA, Basciano P, Lathers D, Tannenbaum-Dvir S, Urbanska K, Kollia G, Darby C, Williams D, Kolaitis G, Ready N. 1528PDInitial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx386.002 |
0.498 |
|
| 2017 |
Juergens R, Chu Q, Rothenstein J, De Angelis F, Banerji S, Marquis K, Sauciuc D, Begin P, Finn N, Hirsh V, Faghih A, Yun J, Li A, Acevedo A, Musallam L, et al. P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients Journal of Thoracic Oncology. 12: S2426-S2427. DOI: 10.1016/J.Jtho.2017.11.088 |
0.4 |
|
| 2017 |
Juergens R, Hao D, Laurie S, Ellis P, Mates M, Bradbury P, Tehfe M, Kollmannsberger C, Arnold A, Goffin J, Wheatley-Price P, Hilton J, Robinson A, Tu D, Brown-Walker P, et al. MA 10.01 Durvalumab ± Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226 Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.533 |
0.463 |
|
| 2017 |
Juergens R, Hellmann M, Brahmer J, Borghaei H, Gettinger S, Chow L, Gerber D, Laurie S, Goldman J, Shepherd F, Geese W, Young T, Li X, Antonia S. OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update Journal of Thoracic Oncology. 12: S1792-S1793. DOI: 10.1016/J.Jtho.2017.09.429 |
0.419 |
|
| 2017 |
Juergens R, Hao D, Laurie S, Mates M, Tehfe M, Bradbury P, Kollmannsberger C, Ellis P, Hilton J, Brown-Walker P, Seymour L. MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226 Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.445 |
0.427 |
|
| 2017 |
Gettinger S, Rizvi N, Chow L, Borghaei H, Brahmer J, Shepherd F, Ready N, Gerber D, Antonia S, Goldman JW, Juergens R, Geese W, Young T, Li X, Hellmann M. OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012 Journal of Thoracic Oncology. 12: S250-S251. DOI: 10.1016/J.Jtho.2016.11.238 |
0.371 |
|
| 2016 |
Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE, Gerber DE, Juergens R, Shepherd F, Laurie SA, Young T, Geese WJ, Agrawal S, Li X, et al. ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S250-S251. PMID 27969442 DOI: 10.1016/J.Jtho.2016.09.008 |
0.369 |
|
| 2016 |
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. The Lancet. Oncology. PMID 27932067 DOI: 10.1016/S1470-2045(16)30624-6 |
0.56 |
|
| 2016 |
Leighl NB, Rizvi NA, de Lima LG, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, ... ... Juergens RA, et al. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer. PMID 27686971 DOI: 10.1016/J.Cllc.2016.07.007 |
0.449 |
|
| 2016 |
Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, et al. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27354485 DOI: 10.1200/Jco.2016.66.9929 |
0.563 |
|
| 2016 |
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, et al. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27354481 DOI: 10.1200/Jco.2016.66.9861 |
0.57 |
|
| 2016 |
Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, et al. Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. Current Oncology (Toronto, Ont.). 23: 196-200. PMID 27330348 DOI: 10.3747/Co.23.3120 |
0.522 |
|
| 2016 |
Yiu KC, Juergens RA, Swaminath A. Multidisciplinary Influence on Care of Lung Cancer Patients at the Time of Diagnosis: a Patient Survey. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 27235380 DOI: 10.1016/J.Clon.2016.04.046 |
0.425 |
|
| 2016 |
Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 1676-88. PMID 26884577 DOI: 10.1200/Jco.2015.63.8049 |
0.492 |
|
| 2016 |
Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens A, Gadgeel SM. Phase I Dose Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26831715 DOI: 10.1158/1078-0432.Ccr-15-2218 |
0.421 |
|
| 2016 |
Hellmann MD, Gettinger SN, Goldman JW, Brahmer JR, Borghaei H, Chow LQ, Ready N, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Zhou Y, Geese WJ, Agrawal S, Li X, et al. CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. Journal of Clinical Oncology. 34: 3001-3001. DOI: 10.1200/Jco.2016.34.15_Suppl.3001 |
0.385 |
|
| 2016 |
Socinski M, Creelan B, Horn L, Reck M, Paz-Ares L, Steins M, Felip E, van den Heuvel M, Ciuleanu T, Badin F, Ready N, Hiltermann T, Nair S, Juergens R, Peters S, et al. NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC Annals of Oncology. 27: vi577. DOI: 10.1093/Annonc/Mdw435.39 |
0.425 |
|
| 2016 |
Hao D, Juergens R, Laurie S, Mates M, Tehfe M, Bradbury P, Kollmannsberger C, Ellis P, Hilton J, Brown-Walker P, Seymour L. A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226) European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32882-9 |
0.44 |
|
| 2015 |
Nicholas GA, Goffin JR, Laurie SA, Robinson AG, Goss GD, Reaume MN, Mates M, Wheatley-Price P, Ellis PM, Juergens RA, Tomiak AT, Gregg RW, Melosky BL, Tu D, Ritter H, et al. A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197. Journal of Clinical Oncology. 33: 8046-8046. DOI: 10.1200/Jco.2015.33.15_Suppl.8046 |
0.434 |
|
| 2015 |
Gettinger SN, Hellmann MD, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQM, Goldman JW, Juergens RA, Borghaei H, Ready N, Gerber DE, Nathan FE, Shen Y, Harbison C, Rizvi NA. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. Journal of Clinical Oncology. 33: 8025-8025. DOI: 10.1200/Jco.2015.33.15_Suppl.8025 |
0.433 |
|
| 2015 |
Hellmann MD, Rizvi N, Gettinger SN, Goldman J, Chow LQ, Juergens R, Borghaei H, Brahmer J, Shen Y, Harbison CT, Nathan F, Ready NE, Antonia SJ. 3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC) European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31738-5 |
0.517 |
|
| 2015 |
Gettinger SN, Hellmann MD, Shepherd FA, Antonia SJ, Brahmer J, Chow LQ, Goldman J, Juergens R, Borghaei H, Ready NE, Gerber DE, Nathan F, Shen Y, Harbison CT, Rizvi N. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31737-3 |
0.413 |
|
| 2014 |
Gettinger S, Rizvi N, Chow LQ, Borghaei H, Brahmer JR, Juergens R, Shepherd FA, Laurie SA, Gerber DE, Goldman J, Shen Y, Harbison C, Chen A, Antonia SJ. 1054PDNIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB (ERL) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv363. PMID 28171125 DOI: 10.1093/Annonc/Mdu342.7 |
0.412 |
|
| 2014 |
Antonia SJ, Brahmer JR, Gettinger SN, Chow LQM, Juergens RA, Shepherd FA, Laurie SA, Gerber DE, Goldman JW, Shen Y, Harbison C, Alaparthy S, Chen AC, Borghaei H, Rizvi NA. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 32: 8113-8113. DOI: 10.1200/Jco.2014.32.15_Suppl.8113 |
0.505 |
|
| 2014 |
Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQM, Juergens RA, Borghaei H, Shen Y, Harbison C, Alaparthy S, Chen AC, Rizvi NA. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. Journal of Clinical Oncology. 32: 8024-8024. DOI: 10.1200/Jco.2014.32.15_Suppl.8024 |
0.367 |
|
| 2014 |
Antonia SJ, Gettinger SN, Chow LQM, Juergens RA, Borghaei H, Shen Y, Harbison C, Chen AC, Ready N, Rizvi NA. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. Journal of Clinical Oncology. 32: 8023-8023. DOI: 10.1200/Jco.2014.32.15_Suppl.8023 |
0.325 |
|
| 2014 |
Antonia SJ, Gettinger S, Goldman J, Chow LQ, Juergens R, Borghaei H, Brahmer JR, Shen Y, Harbison C, Chen AC, Ready NE, Rizvi NA. Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.08.207 |
0.371 |
|
| 2014 |
Rizvi NA, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQ, Goldman J, Juergens R, Borghaei H, Ready NE, Gerber DE, Shen Y, Harbison C, Chen AC, Gettinger S. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.08.204 |
0.49 |
|
| 2014 |
Antonia SJ, Brahmer JR, Gettinger S, Chow LQ, Juergens R, Shepherd FA, Laurie SA, Gerber DE, Goldman J, Shen Y, Harbison C, Chen AC, Borghaei H, Rizvi NA. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC) International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.08.024 |
0.519 |
|
| 2013 |
Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, ... ... Juergens RA, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 4: 2067-79. PMID 24162015 DOI: 10.18632/Oncotarget.1542 |
0.428 |
|
| 2013 |
Tsao A, Hui EP, Juergens R, Marur S, Huat TE, Cher GB, Hong RL, Hong WK, Chan AT. Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. Cancer Medicine. 2: 351-9. PMID 23930212 DOI: 10.1002/Cam4.79 |
0.391 |
|
| 2013 |
Juergens RA, Rudin CM. Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. PMID 23714528 DOI: 10.1200/EdBook_AM.2013.33.e295 |
0.387 |
|
| 2013 |
Halmos B, Jia Y, Bokar JA, Fu P, Adelstein DJ, Juergens R, Rodal MB, Dowlati A. A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. Investigational New Drugs. 31: 1244-1250. PMID 23553066 DOI: 10.1007/S10637-013-9945-8 |
0.378 |
|
| 2013 |
Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P, Liu JO. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 619-23. PMID 23546045 DOI: 10.1097/Jto.0B013E31828C3950 |
0.559 |
|
| 2013 |
Rizvi NA, Antonia SJ, Chow LQM, Brahmer JR, Juergens RA, Borghaei H, Shepherd FA, Laurie SA, Gerber DE, Goldman JW, Shen Y, Harbison C, Alaparthy S, Chen AC, Gettinger SN. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). Journal of Clinical Oncology. 31: 8072-8072. DOI: 10.1200/Jco.2013.31.15_Suppl.8072 |
0.505 |
|
| 2012 |
Levine MN, Juergens R. Method to our madness or madness in our methods? Pitfalls in trial methodology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2025-7. PMID 22547587 DOI: 10.1200/Jco.2011.41.4912 |
0.44 |
|
| 2012 |
Wrangle J, Mohammad HP, Abukhdeir A, Juergens RA, Harbom K, Rodgers K, Shin J, Zahnow CA, Baylin S, Herman JG, Rudin CM, Brock M. Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations. Journal of Clinical Oncology. 30: e18147-e18147. DOI: 10.1200/Jco.2012.30.15_Suppl.E18147 |
0.395 |
|
| 2011 |
Halmos B, Bokar JA, Fu P, Adelstein DJ, Juergens RA, Rodal MB, Dowlati A. A phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14644. PMID 28021356 DOI: 10.1200/Jco.2011.29.15_Suppl.E14644 |
0.413 |
|
| 2011 |
Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discovery. 1: 598-607. PMID 22586682 DOI: 10.1158/2159-8290.Cd-11-0214 |
0.497 |
|
| 2011 |
Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 74: 481-5. PMID 21620511 DOI: 10.1016/J.Lungcan.2011.05.005 |
0.504 |
|
| 2011 |
Rudin CM, Mauer A, Smakal M, Juergens R, Spelda S, Wertheim M, Coates A, McKeegan E, Ansell P, Zhou X, Qian J, Pradhan R, Dowell B, Krivoshik A, Gordon G. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1075-82. PMID 21300929 DOI: 10.1200/Jco.2010.32.5944 |
0.529 |
|
| 2011 |
Juergens R, Vendetti F, Wrangle J, Coleman B, Sebree R, Rudek-Renaut M, Belinsky S, Brock M, Herman J, Baylin S, Rudin C. Abstract LB-411: A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-411 |
0.494 |
|
| 2010 |
Burns TF, Juergens RA. Bevacizumab in advanced lung cancer: in search of the right drug for the right patient. Oncology (Williston Park, N.Y.). 24: 1223-4, 1226. PMID 21192562 |
0.319 |
|
| 2010 |
Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 66: 1079-85. PMID 20165849 DOI: 10.1007/S00280-010-1265-5 |
0.327 |
|
| 2010 |
Juergens RA, Gibson MK, Yang SC, Brock M, Heitmiller R, Tsottles N, Rudek MA, Canto M, Kleinberg L, Forastiere AA. Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC). Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E14532 |
0.428 |
|
| 2009 |
Juergens RA, Vendetti F, Coleman B, Sebree RS, Rudek MA, Belinsky S, Brock M, Herman J, Baylin S, Rudin CM. Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8055. PMID 27962870 DOI: 10.1200/Jco.2009.27.15_Suppl.8055 |
0.447 |
|
| 2008 |
Juergens RA, Forastiere A. Combined modality therapy of esophageal cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 6: 851-60; quiz 861. PMID 18926094 DOI: 10.6004/Jnccn.2008.0063 |
0.399 |
|
| 2008 |
Juergens RA, Vendetti F, Coleman B, Sebree RS, Rudek MA, Belinsky SA, Brock MV, Herman JG, Baylin SB, Rudin CM. Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC) Journal of Clinical Oncology. 26: 19036-19036. DOI: 10.1200/Jco.2008.26.15_Suppl.19036 |
0.446 |
|
| 2007 |
Juergens R, Brahmer J. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Current Oncology Reports. 9: 255-264. PMID 17588349 DOI: 10.1007/S11912-007-0031-2 |
0.413 |
|
| 2007 |
Juergens R, Brahmer J, Ettinger D. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: Sequence does matter Cancer Chemotherapy and Pharmacology. 59: 621-629. PMID 16937106 DOI: 10.1007/S00280-006-0304-8 |
0.494 |
|
| 2006 |
Juergens RA, Brahmer JR. Adjuvant treatment in non-small cell lung cancer: Where are we now? Journal of the National Comprehensive Cancer Network : Jnccn. 4: 595-600. PMID 16813727 DOI: 10.6004/Jnccn.2006.0049 |
0.529 |
|
| 2006 |
Juergens R, Brahmer JR, Ettinger D. Gemcitabine (G) and vinorelbine (V) in patients (pts) with recurrent advanced non-small cell lung cancer (NSCLC): Sequence of administration matters Journal of Clinical Oncology. 24: 17101-17101. DOI: 10.1200/Jco.2006.24.18_Suppl.17101 |
0.43 |
|
| 2005 |
Juergens RA, Brahmer JR. Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future. Current Oncology Reports. 7: 248-54. PMID 15946582 DOI: 10.1007/S11912-005-0046-5 |
0.472 |
|
| Show low-probability matches. |